Inhibrx Biosciences INBX
Inhibrx Biosciences, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)
$73.29-23.38%close on Oct. 28, 2026 · volume 1.2M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 14, 2026 | Mark Lappe Chief Executive Officer, director · indirect | Bought | 10,040 | $84.56 $84.07-$85.76 | $848,977 |
| Sept. 28, 2026 | Mark Lappe Chief Executive Officer, director · indirect | Bought | 4,500 | $100.76 $98.88-$101.70 | $453,426 |
| Sept. 25, 2026 | Mark Lappe Chief Executive Officer, director · indirect | Bought | 5,500 | $99.16 $98.87-$99.60 | $545,357 |
| Sept. 23, 2026 | Jon Faiz Kayyem director · indirect | Bought | 5,000 | $100.00 | $500,000 |
| Sept. 16, 2026 | Jon Faiz Kayyem director · indirect | Bought | 5,000 | $100.00 | $500,000 |
| Sept. 15, 2026 | Kimberly Manhard director · indirect | Sold | 500 | $105.05 | $52,525 |
| Sept. 14, 2026 | Kimberly Manhard director · indirect | Sold | 500 | $110.26 | $55,130 |
| Sept. 11, 2026 | Kimberly Manhard director · indirect | Sold | 500 | $111.78 | $55,888 |
| Sept. 9, 2026 | Kimberly Manhard director · indirect | Sold | 500 | $115.80 | $57,898 |
| Sept. 8, 2026 | Kimberly Manhard director · indirect | Sold | 500 | $115.14 | $57,570 |
| Sept. 8, 2026 | Jon Faiz Kayyem director · indirect | Bought | 5,000 | $113.52 | $567,580 |
| Sept. 8, 2026 | Douglas Forsyth director · indirect | Bought | 2,500 | $114.65 | $286,617 |
Latest 12 of 13. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 22 →Regulation FD disclosure · Financial statements and exhibits